A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-751689 Administered to Healthy Women
Phase 1
Completed
- Conditions
- Osteoporosis
- Registration Number
- NCT00540878
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
This study will examine the effects of formulation on the relative bioavailability of SB-751689 (400 mg) administered to healthy postmenopausal women. Subjects will receive a single oral dose of each formulation, with five formulations of SB-751689 tested in total. Blood samples will be taken up to 24 hours postdose after each dose administration. This study will provide information for future possible formulation development of SB-751689 for Phase III.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method AUC and CMAX after a single dose. after a single dose
- Secondary Outcome Measures
Name Time Method Safety and tolerability after single dose. after a single dose
Trial Locations
- Locations (1)
GSK Investigational Site
πΊπΈPort Orange, Florida, United States